3 research outputs found
CD5 blockade enhances ex vivo CD8+ T cell activation and tumour cell cytotoxicity
CD5 is expressed on T cells and a subset of B cells (B1a). It can attenuate TCR signalling and impair CTL activation and is a therapeutic targetable tumour antigen expressed on leukemic T and B cells. However, the potential therapeutic effect of functionally blocking CD5 to increase T cell antiātumour activity against tumours (including solid tumours) has not been explored. CD5 knockout mice show increased antiātumour immunity: reducing CD5 on CTLs may be therapeutically beneficial to enhance the antiātumour response. Here, we show that ex vivo administration of a functionāblocking antiāCD5 MAb to primary mouse CTLs of both tumourānaĆÆve mice and mice bearing murine 4T1 breast tumour homografts enhanced their capacity to respond to activation by treatment with antiāCD3/antiāCD28 MAbs or 4T1 tumour cell lysates. Furthermore, it enhanced TCR signalling (ERK activation) and increased markers of T cell activation, including proliferation, CD69 levels, IFNāĪ³ production, apoptosis and Fas receptor and Fas ligand levels. Finally, CD5 functionāblocking MAb treatment enhanced the capacity of CD8+ T cells to kill 4T1āmouse tumour cells in an ex vivo assay. These data support the potential of blockade of CD5 function to enhance T cellāmediated antiātumour immunity
2015 Research & Innovation Day Program
A one day showcase of applied research, social innovation, scholarship projects and activities.https://first.fanshawec.ca/cri_cripublications/1002/thumbnail.jp
2016 Research & Innovation Day Program
A one day showcase of applied research, social innovation, scholarship projects and activities.https://first.fanshawec.ca/cri_cripublications/1003/thumbnail.jp